Tiotropium bromide - Glenmark Pharmaceuticals

Drug Profile

Tiotropium bromide - Glenmark Pharmaceuticals

Alternative Names: GSP 304

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Antiasthmatics; Antibronchitics; Epoxy compounds; Esters; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 31 Jul 2017 Glenmark completes a phase II trial in Chronic obstructive pulmonary disease (In adults, In the elderly) in USA (Inhalation) (NCT03118765)
  • 24 Mar 2017 Phase-II clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in USA (Inhalation) (NCT03118765)
  • 07 Mar 2017 Glenmark Pharmaceuticals plans a phase II trial for Chronic obstructive pulmonary disease in India (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top